THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER

Prostate cancer initially responds to androgen-deprivation therapy, but most patients eventually develop a castration-resistant form of disease. Enzalutamid is the superselective inhibitor of the androgen receptor (AR), which blocks several stages of the AR signal path. The drug showed significant e...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: A. A. GRITSKEVICH, S. V. MISHUGIN, I. G. RUSAKOV
स्वरूप: Artigo
भाषा:Russo
प्रकाशित: Remedium Group LLC 2017-06-01
श्रृंखला:Медицинский совет
विषय:
metastatic cancer
enzalutamide
abiraterone acetate
castration resistance
ऑनलाइन पहुंच:https://www.med-sovet.pro/jour/article/view/1894
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन